Tenofovir Alafenamide molecular structure

Tenofovir Alafenamide

Also known as: Vemlidy, Taffic, Tafnat (component of Descovy, Biktarvy, Genvoya, Odefsey)

CAS Number: 379270-37-8

Nucleotide Reverse Transcriptase Inhibitor (NtRTI)

Pharmacopeia Standards

USPIP

Mechanism of Action

Tenofovir alafenamide is a phosphonoamidate prodrug of tenofovir that is preferentially taken up intact by lymphoid cells and hepatocytes, where cathepsin A and carboxylesterase 1 release tenofovir intracellularly. This targeted delivery yields far higher intracellular tenofovir diphosphate at roughly a tenth of the plasma tenofovir exposure seen with the disoproxil prodrug. The active diphosphate is an obligate chain terminator of HIV-1 reverse transcriptase and hepatitis B viral polymerase.

Technical Specifications

Generic / INN NameTenofovir Alafenamide
CAS Registry Number379270-37-8
Molecular FormulaC21H29N6O5P
Molecular Weight476.47 g/mol g/mol
Typical PurityNot less than 98.0% by HPLC; chiral purity of S-isomer not less than 99.0%
Storage ConditionsStore at 2 to 8 degrees C or below 25 degrees C as per specification, in double LDPE bags inside HDPE drums with desiccant, protected from light.
Shelf Life24 to 36 months depending on salt form and packaging configuration
CategoryAntiretrovirals (HIV)

Specifications are indicative and intended for sourcing reference only. Always confirm against the supplier's Certificate of Analysis and the applicable pharmacopeial monograph before issuing a purchase specification.

Typical Applications

Bulk API for low-dose 25 mg hepatitis B tablets and 10 mg or 25 mg strengths within HIV single-tablet regimens combined with emtricitabine, bictegravir, dolutegravir, rilpivirine or elvitegravir/cobicistat.

Manufacturers (0+)

View all →
No manufacturers listed yet. Register your company to appear here.